Churchill Capital Corp XI (CCXIW) — Institutional Holders & Catalysts

Fund Holdings

AI Signal

# Signal Note: Driehaus Initiates Churchill Capital XI SPAC Position **Churchill XI is blank-check vehicle for Ayala Pharmaceuticals (AYLA), focused on oncology with lead program AL101 in GNAQ/GNA11-mutant uveal melanoma.** Driehaus's entry via warrant accumulation (CCXIW) suggests conviction in either upcoming clinical catalysts or post-merger re-rating; AL101 Phase 2 data timing and competitive positioning versus emerging melanoma therapeutics warrant monitoring.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 22,500Value: $230K

# Signal Note: Driehaus Initiates Churchill Capital XI SPAC Position **Churchill XI is blank-check vehicle for Ayala Pharmaceuticals (AYLA), focused on oncology with lead program AL101 in GNAQ/GNA11-mutant uveal melanoma.** Driehaus's entry via warrant accumulation (CCXIW) suggests conviction in either upcoming clinical catalysts or post-merger re-rating; AL101 Phase 2 data timing and competitive positioning versus emerging melanoma therapeutics warrant monitoring. Position sizing (~$230K) indicates modest conviction relative to fund AUM, consistent with early-stage biotech risk assessment.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

Churchill Capital Corp XI

Fund Holdings

Catalysts

Position Details

More CCXIW Analysis

Insider Signals

Also Held by These Funds

Research Links